- Home
- NERV vs PSTV Comparison
NERV vs PSTV Comparison
Compare NERV & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NERV
- PSTV
- Stock Information
- Founded
- NERV 2007
- PSTV 1996
- Country
- NERV United States
- PSTV United States
- Employees
- NERV N/A
- PSTV N/A
- Industry
- NERV Biotechnology: Pharmaceutical Preparations
- PSTV Medical/Dental Instruments
- Sector
- NERV Health Care
- PSTV Health Care
- Exchange
- NERV Nasdaq
- PSTV Nasdaq
- Market Cap
- NERV 12.4M
- PSTV 12.2M
- IPO Year
- NERV 2014
- PSTV N/A
- Fundamental
- Price
- NERV $1.57
- PSTV $0.50
- Analyst Decision
- NERV Hold
- PSTV Strong Buy
- Analyst Count
- NERV 1
- PSTV 3
- Target Price
- NERV $5.00
- PSTV $12.75
- AVG Volume (30 Days)
- NERV 5.9K
- PSTV 3.0M
- Earning Date
- NERV 05-13-2025
- PSTV 05-23-2025
- Dividend Yield
- NERV N/A
- PSTV N/A
- EPS Growth
- NERV N/A
- PSTV N/A
- EPS
- NERV 0.82
- PSTV N/A
- Revenue
- NERV N/A
- PSTV $5,824,000.00
- Revenue This Year
- NERV N/A
- PSTV $13.26
- Revenue Next Year
- NERV N/A
- PSTV $8.84
- P/E Ratio
- NERV $1.95
- PSTV N/A
- Revenue Growth
- NERV N/A
- PSTV 18.54
- 52 Week Low
- NERV $1.15
- PSTV $0.24
- 52 Week High
- NERV $3.69
- PSTV $2.67
- Technical
- Relative Strength Index (RSI)
- NERV 40.93
- PSTV 39.86
- Support Level
- NERV $1.58
- PSTV $0.48
- Resistance Level
- NERV $1.74
- PSTV $0.75
- Average True Range (ATR)
- NERV 0.06
- PSTV 0.10
- MACD
- NERV -0.01
- PSTV -0.00
- Stochastic Oscillator
- NERV 0.00
- PSTV 5.95
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
About PSTV PLUS THERAPEUTICS Inc.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).